131 related articles for article (PubMed ID: 16891806)
1. Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma.
Yun JP; Suh C; Lee E; Chang JW; Yang WS; Park JS; Park SK
J Korean Med Sci; 2006 Aug; 21(4):639-44. PubMed ID: 16891806
[TBL] [Abstract][Full Text] [Related]
2. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
4. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
5. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
8. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
[TBL] [Abstract][Full Text] [Related]
11. Human alpha 1-microglobulin and its relationship to renal function.
Kusano E; Suzuki M; Asano Y; Itoh Y; Takagi K; Kawai T
Nephron; 1985; 41(4):320-4. PubMed ID: 2415841
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
Anagnostopoulos A; Gika D; Hamilos G; Zervas K; Zomas A; Pouli A; Zorzou M; Kastritis E; Anagnostopoulos N; Tassidou A; Anagnostou D; Dimopoulos MA
Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
[TBL] [Abstract][Full Text] [Related]
13. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
15. [Classification, staging and prognostic indices for multiple myeloma].
Hotta T
Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
17. International Staging System required standardization of biochemical laboratory testing in multiple myeloma.
Tichý M; Maisnar V; Palicka V; Friedecký B; Vávrová J; Novotná H; Cermáková Z; Dastych M; Cechák P; Vogtová D; Jarolímková E; Benáková H; Hachová L; Bezdícková D; Kouril F; Zábranská EA; Zenková J; Slabý P; Scudla V; Gregora E; Spicka I; Straub J; Schützova M; Hájek R
Neoplasma; 2006; 53(6):492-4. PubMed ID: 17167717
[TBL] [Abstract][Full Text] [Related]
18. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients.
Kawai K; Kawashima S; Miyazaki T; Tajiri E; Mori M; Kitazaki K; Shirotani T; Inatome T; Yamabe H; Hirata K; Yokoyama M
J Cardiol; 2010 Jan; 55(1):99-107. PubMed ID: 20122555
[TBL] [Abstract][Full Text] [Related]
19. Myeloma progression and urinary gammaglobulin affect the urinary cystatin C to diagnose acute kidney injury in multiple myeloma.
Kim JS; Yang JW; Park H; Kim YS; Lee JY; Lee JI; Han BG; Choi SO
Clin Nephrol; 2014 May; 81(5):345-9. PubMed ID: 24780555
[TBL] [Abstract][Full Text] [Related]
20. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
